Search

The manufacture of goods from oil, coal, or gas to everyday consumer products comprises in more or less all cases at least one catalytic step. Compared to conventional hydrothermal catalysis, electrocatalysis possesses the advantage of mild operational conditions and high selectivity, yet the potential energy savings and climate change mitigation have rarely been assessed. This study conducted a life cycle assessment (LCA) for the electrocatalytic oxidation of crude glycerol to produce lactic acid, one of the most common platform chemicals. The LCA results demonstrated a 31% reduction in global warming potential (GWP) compared to the benchmark (bio- and chemocatalytic) processes. Additionally, electrocatalysis yielded a synergetic potential to mitigate climate change depending on the scenario. For example, electrocatalysis combined with a low-carbon-intensity grid can reduce GWP by 57% if the process yields lactic acid and lignocellulosic biofuel as compared to a conventional fossil-based system with functionally equivalent products. This illustrates the potential of electrocatalysis as an important contributor to climate change mitigation across multiple industries. A technoeconomic analysis (TEA) for electrocatalytic lactic acid production indicated considerable challenges in economic feasibility due to the significant upfront capital cost. This challenge could be largely addressed by enabling dual redox processing to produce separate streams of renewable chemicals and biofuels simultaneously.

Currently used clinical and histopathological parameters imprecisely define the risk of distant recurrence in breast cancer, underscoring the need for more informative prognostic markers. In the present fluorescence in situhybridization study of archived surgical specimens, we derived an algorithm for computing a prognostic index (PI) from DNA copy numbers of three genomic regions (CYP24, PDCD6IP, and BIRC5) for estrogen/progesterone receptor-positive (ER/PR+) cancers and a distinct PI (based on NR1D1, SMARCE1, and BIRC5) for estrogen/progesterone receptor-negative (ER/PR−) cancers. Among independent test cases stratified by PI, recurrence rates were significantly higher among high-risk patients than low-risk patients for both ER/PR+(odds ratio = 9.52, 95% confidence interval 2.12, P= 0.0024) and ER/PR−(odds ratio = 12.3, 95% confidence interval 1.45, P= 0.0188) cancers. Among the entire population, recurrences were significantly more prevalent for cases with PI above the medians for both ER/PR+(Fisher's exact, P= 1.19 × 10−5) and ER/PR−(P= 0.0025) patients and for the node-negative subsets (ER/PR+node-negative, P= 0.042 and ER/PR−node-negative, P= 0.039). In conclusion, these markers perform well in comparison with other criteria for recurrence risk assessment and can be used with routinely formalin-fixed, paraffin-embedded surgical specimens.

In 1996 and 1997, Glaxo Wellcome's US Research division planned and established their second generation research strategy. An important aspect of the strategy entailed development of two automated screening sites in Biochemistry in Research Triangle Park, NC. Development of the new operations required many decisions to be made very quickly, including automated process design, system selection and site preparation. Descriptions of the decision made in the development of one of the screening sites are presented in this paper.

The need for a multiple-target compound selectivity programme led to the establishment of a single robotic system that produces a compound's serial dilution and its distribution to multiple replicate assay plates. A Genesis RSP 150 integrated into a Zymate Laboratory Automation System XP produced the serial dilutions, and the subsequent replicate assay plates were produced quickly and accurately by an efficient use of the carousels and rapid plate. Currently, this process allows for the production of over 200 serial dilution assay plates in a workday.

In 1996 and 1997, Glaxo Wellcome's US Research division planned and established their second generation research strategy. An important aspect of the strategy entailed development of two automated screening sites in Biochemistry in Research Triangle Park, NC. Development of the new operations required many decisions to be made very quickly, including automated process design, system selection and site preparation. Descriptions of the decision made in the development of one of the screening sites are presented in this paper.

In 1996 and 1997, Glaxo Wellcome's US Research division planned and established their second generation research strategy. An important aspect of the strategy entailed development of two automated screening sites in Biochemistry in Research Triangle Park, NC. Development of the new operations required many decisions to be made very quickly, including automated process design, system selection and site preparation. Descriptions of the decision made in the development of one of the screening sites are presented in this paper.